Nordea Investment Management AB trimmed its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 12.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,505,862 shares of the biopharmaceutical company's stock after selling 815,575 shares during the period. Nordea Investment Management AB owned approximately 0.27% of Bristol-Myers Squibb worth $310,861,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. First City Capital Management Inc. raised its holdings in Bristol-Myers Squibb by 1.0% during the fourth quarter. First City Capital Management Inc. now owns 21,164 shares of the biopharmaceutical company's stock worth $1,197,000 after buying an additional 219 shares during the last quarter. GAMMA Investing LLC raised its position in Bristol-Myers Squibb by 22.0% in the 4th quarter. GAMMA Investing LLC now owns 33,418 shares of the biopharmaceutical company's stock valued at $1,890,000 after buying an additional 6,032 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Bristol-Myers Squibb by 14.0% during the 4th quarter. Versant Capital Management Inc now owns 78,690 shares of the biopharmaceutical company's stock worth $4,451,000 after acquiring an additional 9,692 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Bristol-Myers Squibb by 4.4% during the 3rd quarter. Principal Financial Group Inc. now owns 2,458,536 shares of the biopharmaceutical company's stock worth $127,205,000 after buying an additional 102,790 shares in the last quarter. Finally, Exome Asset Management LLC purchased a new position in Bristol-Myers Squibb in the third quarter worth $4,036,000. Institutional investors own 76.41% of the company's stock.
Several equities analysts recently weighed in on BMY shares. TD Cowen increased their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and boosted their price objective for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Barclays boosted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a report on Monday, October 7th. Daiwa America raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 13th. Finally, Leerink Partners upgraded Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Hold" and an average price target of $55.64.
Get Our Latest Research Report on BMY
Shares of NYSE:BMY opened at $56.57 on Monday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The stock's fifty day moving average price is $57.14 and its 200-day moving average price is $51.04. The company has a market cap of $114.73 billion, a P/E ratio of -15.76, a PEG ratio of 15.20 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company posted $2.00 earnings per share. Sell-side analysts expect that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be issued a $0.62 dividend. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a yield of 4.38%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -69.08%.
In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,830 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares of the company's stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company's stock, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.